Cyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation – a retrospective analysis
There have been significant improvements in therapeutic options for relapsed multiple myeloma (MM) over the past two decades, with many novel agents including proteasome inhibitors, immunomodulatory agents, and more recently monoclonal antibodies demonstrating efficacy in this setting. However, ther...
Guardado en:
Autores principales: | Russell Sterrett, Amarilis Figueiredo, Ranjeeta Mallick, Natasha Kekre, Harold Atkins, Arleigh McCurdy |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/855b6e849f604315b0e9b1d6256a2e6b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide
por: Schoenbeck KL, et al.
Publicado: (2020) -
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
por: Bhutani D, et al.
Publicado: (2017) -
Therapy of Angiosarcoma with Thalidomide and Lenalidomide
por: M. Jules Mattes, et al.
Publicado: (2021) -
Sequential Transplantation of Haploidentical Stem Cell and Unrelated Cord Blood With Using ATG/PTCY Increases Survival of Relapsed/Refractory Hematologic Malignancies
por: Hua Li, et al.
Publicado: (2021) -
Mieloma múltiple en Chile: pasado, presente y futuro del programa nacional de drogas antineoplásicas (PANDA). Revisión de 1.103 pacientes
por: Peña,Camila, et al.
Publicado: (2018)